GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

China Regenerative Medicine International 8158.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

0.24

+4.35%

Close of 4 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About China Regenerative Medicine International

Its shares trade on HKEX under the ticker 8158.HK. It has been listed since 18 July 2001. In the fiscal year to 31 December 2025, it reported net income of HK$27.5m. At that date it held total assets of HK$168.1m and shareholders' equity of HK$53.5m.

China Regenerative Medicine International Ltd is a HK-based company operating in Biotechnology industry. The company employs 23 full-time employees The company went IPO on 2001-07-18. China Regenerative Medicine International Ltd is an investment holding company mainly engaged in the provision of comprehensive health products and services. The firm is engaged in the supply and sale of medical products and medical equipment. In addition, the Company is engaged in the provision of various health management services such as health assessment, detoxification treatment, homeostasis, organ maintenance and immune system enhancement.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
18 Jul 2001
Employees
23
Website
crmi.hk ↗

Leadership

Pay as last reported

  • Mr. Chuang WangExecutive Chairman of the Board, Chief Executive Officer, Compliance Officer, since 2019HK$1.2m
  • Mr. Po Tin WongChief Financial Officer, Company Secretary
  • Ms. Chunyu HuoNon-Executive Independent DirectorHK$120,000
  • Mr. Man Fai LeungNon-Executive Independent DirectorHK$1,000
  • Dr. Ming LiuNon-Executive Independent DirectorHK$1,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • HK-based company with 23 employees in Biotechnology sector.
  • Provides comprehensive health products and services including medical equipment supply.
  • Offers health management services like detoxification and immune system enhancement.

Weaknesses

  • 23 full-time employees limit operational scale in Biotechnology.
  • IPO listed in 2001 may indicate outdated business model.
  • Limited to HK-based operations without global expansion.

Opportunities

  • Growing demand for health management services in Asia.
  • Expansion into medical equipment supply markets globally.
  • Increasing focus on immune system enhancement in healthcare.

Threats

  • Biotechnology sector competition from larger firms.
  • Healthcare regulations may restrict service offerings.
  • Economic downturns affecting health product sales.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.